SYK 10-K Annual Reports

Stryker Corporation reported strong performance for the fiscal year 2025, with net sales growing by 11.2% to $25,116 million, driven by robust increases in both its MedSurg and Neurotechnology segment (up 15.7%) and its Orthopaedics segment (up 4.3%). This growth was primarily fueled by increased unit volume across all businesses, with a notable contribution from the acquisition of Inari Medical, Inc. The company also demonstrated improved profitability, with gross profit increasing and operating income rising to $4,889 million, reflecting effective pricing strategies and favorable volume dynamics. Financially, Stryker maintained a healthy liquidity position, with significant cash flow from operations and substantial cash reserves. The company continued its capital allocation strategy, investing heavily in acquisitions totaling $4,960 million, while also returning capital to shareholders through dividends. Despite macroeconomic headwinds and ongoing investments in growth initiatives, Stryker has reaffirmed its commitment to innovation and expanding its product offerings, particularly in areas like robotic-assisted surgery and minimally invasive treatments, positioning it for continued success in the dynamic medical technology landscape.

Stryker Corporation's 2024 10-K filing highlights a year of robust growth and strategic acquisitions, underscoring its position as a global leader in medical technologies. The company reported a 10.2% increase in net sales, reaching $22.595 billion, driven by strong performance across both its MedSurg and Neurotechnology (up 11.1%) and Orthopaedics (up 8.9%) segments. This growth was fueled by increased unit volumes and, to a lesser extent, higher pricing, demonstrating resilience in a dynamic healthcare market. The company also completed several strategic acquisitions totaling $1.628 billion, further expanding its product portfolios and market reach. Financially, Stryker maintained healthy profitability with a gross profit margin of 63.9%. However, net earnings saw a slight decrease to $2.993 billion from $3.165 billion in the prior year, partly due to significant goodwill impairments related to its Spine business, amounting to $456 million, and a $362 million loss recognized on assets held for sale within the Spinal Implants business. Despite these charges, operating income remained strong. The company continued its commitment to capital allocation, investing in acquisitions, paying $1.219 billion in dividends, and maintaining a strong liquidity position with $3.743 billion in cash, cash equivalents, and marketable securities.

Stryker Corporation's 2023 10-K filing highlights robust top-line growth driven by strong unit volume increases across its MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The company reported net sales of $20.5 billion, an increase of 11.1% year-over-year, with constant currency growth at 11.6%. This growth was supported by product innovation and market expansion, including the acquisition of Cerus Endovascular. Profitability showed improvement, with operating income rising significantly, reflecting effective cost management and favorable pricing, though offset by increased manufacturing and supply chain costs. Stryker continues to prioritize its capital allocation strategy, investing in acquisitions, returning capital to shareholders through dividends, and engaging in share repurchases. The company maintains a strong liquidity position, with substantial cash from operations and access to credit markets. Key operational risks identified include supply chain disruptions, inflationary pressures, pricing pressures within the healthcare industry, and regulatory compliance. The company's robust risk management framework, including cybersecurity, is actively overseen by management and the Board of Directors.

Stryker Corporation reported net sales of $18.45 billion for the fiscal year ended December 30, 2022, a 7.8% increase from the prior year, or 11.0% in constant currency. The company's performance was driven by robust growth in its MedSurg and Neurotechnology segment, which increased 11.2% (14.1% in constant currency), while the Orthopaedics and Spine segment saw a more modest 3.5% increase (7.0% in constant currency). Despite top-line growth, profitability faced headwinds from inflationary pressures, primarily impacting labor, steel, and transportation costs, as well as electronic component shortages that constrained supply. These factors, coupled with unfavorable foreign exchange rates, led to a decrease in gross profit margin to 62.8% from 64.1% in the prior year. The company also recorded a significant goodwill impairment charge of $216 million related to its Spine business. Net earnings were $2.36 billion, or $6.17 per diluted share, representing an 18.3% increase year-over-year. Excluding certain items, adjusted net earnings per diluted share grew 2.8% to $9.34. Stryker continued its strategic capital allocation by investing $2.56 billion in acquisitions, notably the acquisition of Vocera Communications, Inc., and returning capital to shareholders through $1.05 billion in dividend payments. The company faces ongoing risks including supply chain disruptions, inflationary pressures, and regulatory complexities, particularly with the implementation of new medical device regulations in the EU and UK, and volume-based procurement programs in China.

Stryker Corporation's 2021 10-K filing reveals a strong recovery and growth trajectory following the disruptions of 2020. The company reported a 19.2% increase in net sales, reaching $17.1 billion, with organic growth of 13.4% driven by increased unit volume across most product lines. The company's strategic focus on key segments like MedSurg and Neurotechnology, and Orthopaedics and Spine, has yielded positive results. Significant growth was observed in the Orthopaedics and Spine segment, up 26.0%, indicating a robust rebound in elective procedures. Stryker continues to invest in innovation and acquisitions, with the notable pending acquisition of Vocera Communications, Inc. for approximately $3.1 billion, aiming to further enhance its market position and service offerings.

Stryker Corporation's 2020 10-K filing reveals a company navigating the complexities of the COVID-19 pandemic, which led to a 3.6% decline in net sales compared to 2019. Despite this, Stryker demonstrated resilience through strategic acquisitions, notably the significant purchase of Wright Medical Group N.V., which expanded its portfolio in trauma and extremities. The company maintained a strong focus on its core segments: Orthopaedics, MedSurg, and Neurotechnology and Spine, with MedSurg representing the largest segment by sales in 2020. Financially, Stryker reported net earnings of $1.6 billion, a decrease from the previous year, impacted by pandemic-related disruptions and increased interest expenses due to debt financing for acquisitions. However, operating cash flow remained robust, and the company prioritized its capital allocation strategy by investing heavily in acquisitions and continuing dividend payments, while suspending share repurchases for 2020 and 2021. Management highlighted the successful integration of acquisitions and ongoing efforts to drive innovation and operational efficiency amidst evolving market conditions and regulatory landscapes.

Stryker Corporation's 2019 Form 10-K report details a year of robust growth and strategic investments. The company achieved a reported net sales increase of 9.4%, reaching $14.88 billion, driven by strong performance across its Orthopaedics, MedSurg, and Neurotechnology and Spine segments. Excluding the impact of acquisitions and currency fluctuations, sales grew by 9.0% on a constant currency basis, primarily due to increased unit volume. Financially, Stryker reported net earnings of $2.08 billion, or $5.48 per diluted share. However, excluding certain non-recurring items and acquisition-related costs, adjusted net earnings grew by 13.0% to $3.14 billion. The company continued its capital allocation strategy, investing $802 million in acquisitions, paying $778 million in dividends, and repurchasing $307 million in stock. A significant development was the announcement of a definitive agreement to acquire Wright Medical Group N.V. for approximately $5.4 billion, expected to close in the second half of 2020, which will bolster Stryker's extremities and biologics offerings.

Stryker Corporation's 2018 10-K filing highlights a strong year characterized by significant revenue growth and strategic acquisitions. The company reported total net sales of $13.6 billion, representing a 9.3% increase over the prior year, driven by both organic growth and contributions from recent acquisitions. This growth was observed across all three reporting segments: Orthopaedics, MedSurg, and Neurotechnology and Spine, with Neurotechnology and Spine showing particularly robust expansion. Financially, Stryker demonstrated solid performance, with net earnings of $3.55 billion and diluted earnings per share of $9.34. The company continued its commitment to returning value to shareholders through a balanced capital allocation strategy that included substantial investments in acquisitions, dividend payments, and share repurchases. Key strategic moves during the year included the acquisitions of K2M Group Holdings, Inc. and Entellus Medical, Inc., aimed at strengthening their positions in the spine and neurotechnology markets, respectively. Looking ahead, Stryker faces various risks including regulatory scrutiny, competitive pressures, and the evolving healthcare landscape. However, the company's diversified product portfolio, focus on innovation, and strategic acquisitions position it well for continued growth and market leadership in the medical technology sector.

Stryker Corporation's 2017 10-K filing reveals a company demonstrating robust growth and strategic acquisitions in the medical technology sector. Total net sales increased by 9.9% to $12.44 billion, driven by strong performance in the MedSurg and Orthopaedics segments, with organic sales growth of 8.2% excluding acquisitions and currency impacts. The company's strategic focus on acquisitions is evident with the completion of NOVADAQ and the announced agreement to acquire Entellus Medical, underscoring its commitment to expanding its innovative product portfolio and market reach. While the company reported a decrease in net earnings to $1.02 billion from $1.65 billion in the prior year, largely impacted by a significant one-time tax expense related to the Tax Cuts and Jobs Act of 2017, the underlying operational performance remains strong. Adjusted net earnings per diluted share saw a healthy increase of 11.9%. Investors should note the ongoing legal proceedings, particularly related to the Rejuvenate and ABG II hip stems recall, which continues to represent a significant financial contingency, though the company has established reserves for these matters.

Stryker Corporation's 2016 Form 10-K highlights a strong year of growth, with net sales increasing by 13.9% to $11.3 billion, driven by robust performance across its business segments, particularly MedSurg and Neurotechnology and Spine. The company successfully executed its strategic capital allocation, investing significantly in acquisitions, notably Sage Products and Physio-Control, which are expected to bolster its offerings in intensive care disposable products and emergency medical equipment, respectively. While reporting net earnings of $1.65 billion, an increase from the previous year, investors should note the impact of recall charges related to the Rejuvenate and ABG II hip stems, which continue to affect the company's financial results, though at a reduced level compared to prior years. The company also demonstrated a commitment to shareholder returns through dividend payments. Looking ahead, Stryker is well-positioned with a diversified product portfolio and a continued focus on innovation, as evidenced by its consistent investment in research and development. The company faces a competitive landscape and regulatory scrutiny, common in the medical technology sector, but its strong financial position, including significant cash and credit facilities, provides a solid foundation for future growth and its strategic objectives, including further acquisitions and organic expansion. Investors should monitor the ongoing resolution of product liability matters and the company's ability to integrate recent acquisitions successfully.

Stryker Corporation's 2015 10-K filing reports on a year of moderate revenue growth, driven by increased unit volume and product mix, partially offset by pricing pressures and currency headwinds. The company's diverse medical technology portfolio, spanning Orthopaedics, MedSurg, and Neurotechnology & Spine, generated $9.95 billion in net sales. Net earnings saw a significant increase to $1.44 billion, largely due to a substantial reduction in recall charges compared to the prior year. Despite ongoing investments in R&D and strategic acquisitions, the company maintained a strong financial position with robust operating cash flow and significant liquidity. Investors should note the ongoing impact of the Rejuvenate and ABG II hip stem recall, which continues to incur charges, though at a reduced level. The company also highlighted its capital allocation strategy prioritizing acquisitions, dividends, and share repurchases.

Stryker Corporation's 2014 Form 10-K reveals a company with robust revenue growth, achieving $9.675 billion in net sales, a 7.3% increase year-over-year. This growth was driven by strong performance across its three key segments: Orthopaedics, MedSurg, and Neurotechnology and Spine, with particular strength noted in instruments, trauma and extremities, and neurotechnology products. The company continued its strategic focus on acquisitions, investing $916 million in 2014 to expand its product offerings and market reach. However, net earnings experienced a significant decline of 48.8% to $515 million, largely impacted by substantial recall charges related to hip stems, totaling $761 million. Despite this, Stryker maintained a strong financial position with $5 billion in cash, cash equivalents, and marketable securities, indicating good liquidity. The company also demonstrated its commitment to returning value to shareholders through dividend payments and share repurchases, while continuing to invest in research and development to fuel future innovation.

Stryker Corporation reported total revenues of $9.02 billion for the fiscal year ended December 30, 2013, a 4.2% increase over the prior year. Net earnings for the period were $1.01 billion, a decrease of 22.5% compared to $1.30 billion in 2012. This decline in net earnings was significantly influenced by charges related to product recalls, specifically the Rejuvenate and ABG II hip stems, as well as acquisition and integration costs. The company demonstrated revenue growth across its three main segments: Reconstructive, MedSurg, and Neurotechnology and Spine, driven primarily by increased unit volumes, particularly in trauma and extremities products, neurotechnology, hips, and endoscopy. Stryker continued its strategic acquisition approach, notably acquiring MAKO Surgical Corp. for approximately $1.68 billion to enhance its robotic-assisted surgery capabilities and Trauson Holdings Company Limited for $751 million to expand its presence in China and the value segment of emerging markets. The company also announced its intent to acquire Patient Safety Technologies, Inc. in early 2014. Despite ongoing legal and regulatory matters, including reserves for the hip stem recalls totaling between $790 million and $1.235 billion, Stryker maintained a strong balance sheet with significant cash and cash equivalents. The company also increased its dividend payments and continued share repurchases, signaling confidence in its financial position and future prospects.

Stryker Corporation's 2012 10-K filing reveals a company with robust revenue growth and diverse product segments, including Reconstructive, MedSurg, and Neurotechnology and Spine. In 2012, the company generated $8.66 billion in net sales and $1.30 billion in net earnings. The Reconstructive segment, primarily focused on joint replacements, showed steady growth, while MedSurg, encompassing surgical equipment and systems, also saw increases. The Neurotechnology and Spine segment experienced significant growth, largely driven by strategic acquisitions that expanded its product offerings in neurovascular and spinal devices. The company highlights its commitment to innovation, with ongoing research and development investments, and strategic acquisitions to bolster its portfolio. However, Stryker also faces several risks, including potential impacts from healthcare reform legislation, particularly the 2.3% medical device excise tax, pricing pressures due to cost containment measures, and significant legal and regulatory risks, including ongoing product liability lawsuits and investigations. Despite these challenges, Stryker demonstrated strong operating cash flow and maintained a healthy liquidity position.

This filing, an amendment to Stryker Corporation's 2011 10-K, focuses on the company's internal controls over financial reporting as of December 31, 2011. Management, including key executive officers, has concluded that the company's disclosure controls and procedures are effective. Furthermore, internal control over financial reporting is also deemed effective, based on the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). No changes materially affecting internal controls were noted during the fourth quarter of 2011. An important point for investors is the temporary exclusion of the recently acquired Neurovascular business from the internal control assessment. This exclusion, permitted by SEC guidance for acquired businesses, covers a period of one year. While this business represents a notable portion of Stryker's assets, equity, and revenue (13%, 7%, and 4% respectively), the company's overall internal control framework remains robust according to both management and the independent auditor, Ernst & Young LLP. Stryker is also actively implementing new Enterprise Resource Planning (ERP) systems, which are being integrated with updates to internal controls without anticipated adverse effects.

Stryker Corporation reported robust revenue growth in 2011, driven by strong performance across its three key segments: Reconstructive, MedSurg, and Neurotechnology and Spine. The company's strategic acquisitions, particularly the significant Neurovascular division acquisition from Boston Scientific, played a crucial role in expanding its market presence and product portfolio, especially in the neurotechnology space. Despite a challenging economic environment and increased R&D investments, Stryker demonstrated solid operational execution, with notable revenue increases in both domestic and international markets. The company also managed its costs effectively, although certain one-time charges related to restructuring and acquisition integration impacted reported net earnings. Stryker's financial position remains strong, supported by healthy operating cash flow and a well-managed debt structure, allowing for continued investment in innovation and shareholder returns through dividends and share repurchases.

Stryker Corporation's 2010 Form 10-K highlights a year of solid growth, with total net sales increasing by 9% to $7.32 billion. This growth was driven by a combination of increased unit volume, strategic acquisitions, and favorable foreign currency exchange rates, partially offset by pricing changes. The company's performance was supported by strong sales in both its Orthopaedic Implants and MedSurg Equipment segments. The Orthopaedic Implants segment saw a 5% increase in sales, primarily driven by hip, knee, and trauma implant systems, while the MedSurg Equipment segment experienced a significant 16% jump, bolstered by surgical equipment, navigation systems, and patient handling products. The company also made strategic acquisitions throughout the year, including key assets in the neurovascular market, which are expected to enhance its product portfolio and market presence. Financially, Stryker demonstrated robust operational cash flow and a strong balance sheet, enabling it to fund acquisitions, dividends, and stock repurchases. Despite some ongoing legal and regulatory matters, the company maintained effective internal controls and expressed confidence in its ability to fund future operations and growth initiatives.

Stryker Corporation's 2009 10-K report reveals a company with stable net sales of $6.72 billion, showing minimal growth year-over-year, largely due to the economic downturn impacting its MedSurg Equipment segment. Despite this, the Orthopaedic Implants segment demonstrated resilience with a 4% increase in sales, driven by strong performance in hip, knee, trauma, and spinal implant systems. The company made a significant strategic acquisition of Ascent Healthcare Solutions for $525 million in cash, aiming to bolster its MedSurg segment. Stryker also managed its expenses effectively, reducing R&D spending as a percentage of sales and controlling SG&A expenses, which, combined with a patent litigation gain, helped offset some of the impacts from restructuring charges and higher cost of sales. Investors should note the ongoing regulatory scrutiny, including FDA warning letters at several facilities, though one has been resolved. The company also highlighted its strong liquidity position and access to credit facilities to fund future operations and growth initiatives.

Stryker Corporation's 2008 10-K filing reveals a robust year of growth, with net sales reaching $6.7 billion, a 12% increase over 2007. This growth was driven by strong performance across both its Orthopaedic Implants and MedSurg Equipment segments, with international sales showing a notable 13% increase. Despite a challenging economic climate, particularly impacting hospital capital budgets in the latter half of the year, Stryker demonstrated resilience, with significant sales increases in key areas like knee implants (14%), trauma implants (18%), and patient handling equipment (18%). The company also reported a 16% increase in net earnings from continuing operations to $1.15 billion. Management highlighted its focus on innovation and new product introductions, such as the Tritanium Primary Hip System and the S3 Med/Surg Hospital Bed, as critical to its growth strategy. While the company faced some regulatory challenges, including warning letters related to quality systems, it actively cooperated with authorities to address these issues. Stryker also continued its share repurchase program, underscoring its commitment to returning value to shareholders.

This filing for Stryker Corporation (SYK) pertains to its 2007 annual report, specifically an amendment (10-K/A) filed on March 3, 2008. The filing primarily incorporates by reference information from the company's 2008 proxy statement regarding its directors and corporate governance. It also provides details on the company's executive officers as of January 31, 2008, including their roles, tenure, and prior experience. Investors can gain insight into the leadership team's background, which can be a crucial factor in assessing management's capabilities and strategic direction. The report highlights the established corporate governance framework, with key documents such as Corporate Governance Guidelines, committee charters (Audit, Governance and Nominating, Compensation), and the Code of Ethics readily available on the company's website and upon written request. This emphasis on transparency and structured governance is a positive signal for investors concerned with ethical business practices and oversight. The filing also lists the certifications required by Rule 13a-14(a) for the Principal Executive Officer and Principal Financial Officer, underscoring compliance with regulatory standards.

Stryker Corporation's 2007 Form 10-K details a year of robust growth, with net sales increasing 17% to $6.0 billion, driven by strong performance in both its Orthopaedic Implants and MedSurg Equipment segments. The company experienced broad-based sales growth across key product lines, including hip and knee implants, trauma systems, and surgical equipment. This growth was fueled by new product introductions and continued investment in research and development, which represented 6.3% of sales. Operationally, Stryker demonstrated improved profitability, with net earnings from continuing operations up 28% year-over-year. The company successfully managed its cost of sales and selling, general, and administrative expenses relative to sales, indicating operational efficiency. While facing some regulatory scrutiny, including FDA warning letters regarding quality systems, Stryker is actively addressing these concerns and maintains a positive outlook for 2008, projecting a 22% increase in diluted net earnings per share. The company also reports a healthy financial position with ample liquidity and borrowing capacity.

Stryker Corporation's 2006 10-K filing reveals a robust year of growth and strategic acquisitions, positioning the company as a leader in medical technology. The company reported net sales of $5.41 billion, an 11% increase year-over-year, driven by strong performance in both its Orthopaedic Implants and MedSurg Equipment segments. Significant product launches and the successful integration of recent acquisitions, including Sightline Technologies, PlasmaSol, and eTrauma, contributed to this growth. Financially, Stryker demonstrated solid profitability, with net earnings of $777.7 million, a 21% increase from the previous year. The company's investment in research and development (R&D) increased to 6.0% of sales, reflecting a commitment to innovation and future product pipelines, particularly in advanced implant technologies and surgical equipment. The company maintained a strong balance sheet with substantial cash and marketable securities, providing ample resources for ongoing operations, potential future acquisitions, and shareholder returns.

Stryker Corporation's 2005 10-K report highlights a strong year of growth, with net sales increasing 14% to $4.87 billion, driven by robust performance in both its Orthopaedic Implants and MedSurg Equipment segments. The company completed a significant repatriation of $722 million in foreign earnings, leveraging the American Jobs Creation Act, which will be reinvested domestically. Strategic acquisitions played a key role, with the integration of PlasmaSol Corp. and eTrauma.com Corp. bolstering Stryker's product offerings in sterilization equipment and digital imaging, respectively. The company also made substantial investments in research and development, increasing R&D spending to 5.7% of sales, underscoring its commitment to innovation. Looking ahead, Stryker projected continued growth and earnings per share expansion in 2006, signaling confidence in its market position and product pipeline.

Stryker Corporation's 2004 Form 10-K highlights a year of significant growth and strategic acquisitions. The company demonstrated robust top-line expansion with net sales increasing by 18% to $4.26 billion, driven by strong performance in both its Orthopaedic Implants and MedSurg Equipment segments. This growth was fueled by increased unit volume, favorable foreign currency exchange rates, and strategic price adjustments. A notable event was the acquisition of SpineCore, Inc., which is expected to bolster Stryker's position in the growing spinal implant market. Operationally, Stryker reported an increase in operating income and net earnings, although reported net earnings saw a smaller increase due to a significant charge for purchased in-process research and development related to the SpineCore acquisition. Excluding this one-time charge, adjusted net earnings showed a substantial increase of 29%, underscoring the underlying strength of the business. The company also continued its investment in research and development, with expenditures increasing by 17% to support new product launches and future growth initiatives.

Stryker Corporation's 2003 Form 10-K report showcases a company with robust growth and a diversified product portfolio in the orthopaedics and medical technology sectors. The company achieved a significant 20% increase in net sales, reaching $3.6 billion, driven by strong performance in both its Orthopaedic Implants and MedSurg Equipment segments. This growth was fueled by increased unit volume, higher selling prices, and favorable foreign currency exchange rates. Stryker's strategic acquisitions, such as the Surgical Dynamics Inc. spinal implant business, further bolstered its product offerings and market position. Financially, Stryker demonstrated strong profitability, with net earnings increasing by 31% to $453.5 million. The company also managed its debt effectively, with total borrowings declining significantly. Looking ahead, Stryker expressed optimism for 2004, anticipating continued sales growth and a focus on investing in future business expansion, including potential acquisitions. The company's commitment to research and development, evidenced by increased R&D spending, and its expanding international presence highlight its strategy for sustained long-term growth and market leadership.

Stryker Corporation's 2002 10-K report highlights a strong year of growth, with net sales increasing by 16% to $3,011.6 million. This growth was driven by robust performance in both its Orthopaedic Implants and MedSurg Equipment segments, with particular strength in reconstructive, trauma, and spinal implants, as well as powered surgical instruments and endoscopic systems. The company also successfully integrated several strategic acquisitions, including Surgical Dynamics Inc. (SDI), which expanded its spinal product offerings. Financially, Stryker demonstrated improved profitability, with net earnings up 29% year-over-year, and effective management of expenses, including a decrease in research, development, and engineering as a percentage of sales due to the commercial launch of its OP-1 product. The company's liquidity remains strong, supported by significant cash flow from operations and substantial available borrowing capacity, enabling continued investment in product development and strategic acquisitions.

Stryker Corporation's 2001 10-K report highlights a year of significant growth, with net sales increasing by 14% to $2.6 billion. This growth was driven by a robust performance in both its Orthopaedic Implants and MedSurg Equipment segments. The company successfully navigated a dynamic market, marked by strategic acquisitions and a strong focus on research and development, evidenced by a 16% increase in R&D expenses. Financially, Stryker demonstrated improved profitability and liquidity. Net earnings saw a substantial increase of 21% to $267 million. The company also enhanced its financial flexibility through refinancing its credit facilities. Despite ongoing healthcare cost containment measures, Stryker's commitment to innovation and its broad product portfolio position it well for continued expansion in the specialty surgical and medical products market.

Stryker Corporation's 1995 10-K filing reveals a company focused on orthopedics, medical, and surgical products. While the provided text is primarily a directory listing from the SEC's EDGAR database and lacks detailed financial statements or management discussion, it indicates the company was active and making its required filings in 1996. Investors would look to a full 10-K to understand the company's financial performance, strategic direction, product pipeline, competitive landscape, and any potential risks or opportunities. Given the limited information, it's challenging to provide specific financial insights. However, the filing date of March 28, 1996, for the period ending December 30, 1995, suggests a year-end review. Investors would typically expect to see information on revenue growth, profitability, debt levels, cash flow, and any significant acquisitions or divestitures that shaped the company's performance during 1995.

Stryker Corporation's 1994 10-K filing, amended and filed in May 1995, provides a snapshot of the company's performance and strategic direction as of the fiscal year ending December 30, 1994. As a leader in the medical technology sector, Stryker's report highlights its focus on innovation, product development, and expanding its market presence in orthopedic implants, surgical instruments, and neurotechnology. The filing likely details the company's financial health, including revenue growth, profitability, and investments in research and development, crucial indicators for investors assessing its long-term value and competitive standing.

This 10-K filing for Stryker Corporation (SYK) covers the fiscal year ending December 30, 1994. As of March 24, 1995, the company was operating within the medical technology sector, likely focusing on surgical instruments, implants, and related products. Investors would be interested in the company's financial performance, strategic direction, and any notable developments during the reporting period. The filing would provide detailed financial statements, management's discussion and analysis (MD&A) of financial condition and results of operations, and information on the company's business segments, risks, and legal proceedings.

Stryker Corporation's 1993 annual report (filed in March 1994) reflects a company operating in the medical technology sector. While specific financial performance metrics are not detailed in the provided excerpt, the filing indicates the company is disclosing its year-end information for 1993. Investors should note the date of the filing, which is critical for understanding the historical context of the company's performance and strategic positioning at that time.